The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 74-year-old female with generalized anxiety disorder was started on escitalopram 5 mg daily eight weeks ago. At follow-up, her GAD-7 score has decreased from 18 to 11, representing a 39% reduction. She reports less constant worry and improved sleep onset latency, but continues to endorse persistent somatic anxiety symptoms including muscle tension, restless feelings, and fatigue. She denies falls, cognitive changes, or medication side effects. Her daughter reports the patient appears somewhat less anxious overall but remains notably tense and has difficulty relaxing during family gatherings. The PMHNP is evaluating the treatment response in the context of geriatric prescribing considerations. Which of the following best represents the appropriate evaluation of this patient's treatment trajectory?
Explanation
Evaluating anxiety treatment in geriatric patients requires balancing dose optimization within age-appropriate safety parameters, screening for medical comorbidities contributing to persistent symptoms, and integrating non-pharmacological interventions. The 10 mg maximum dose of escitalopram for patients over 65 due to QTc risk is a critical geriatric prescribing consideration.
Key Takeaway
Geriatric anxiety evaluation must account for age-specific dosing limitations such as the escitalopram 10 mg maximum for patients over 65, medical comorbidity screening, and the need for multimodal approaches to address persistent somatic symptoms.